Related Experiment Video
Updated: Jul 17, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
New anticoagulants: from bench to bedside.
1Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany. sylvia.haas@lrz.tum.de
Hamostaseologie
|February 7, 2007
Summary
New anticoagulants targeting specific factors in blood clotting offer safer and more predictable alternatives to traditional therapies like heparins and vitamin K antagonists.
Area of Science:
- Pharmacology and Medicine
- Hematology
Background:
- Heparins and vitamin K antagonists are established anticoagulants but have practical limitations.
- Developing safer, more convenient, and specific anticoagulation therapies is a significant challenge.
- These limitations necessitate novel agents with predictable anticoagulant responses.
Purpose of the Study:
- To review advances in anticoagulation therapy.
- To explore novel agents targeting specific steps in the coagulation cascade.
- To assess the potential of new anticoagulants in managing thromboembolic disorders.
Main Methods:
- Review of scientific literature on anticoagulation therapies.
- Analysis of different targets within the coagulation cascade.
- Evaluation of clinical development of novel anticoagulant agents.
Main Results:
- Significant advances have been made in developing safer and more specific anticoagulants.
- Direct factor Xa and factor IIa inhibitors show advanced clinical development.
- These novel agents aim to overcome the limitations of conventional anticoagulants.
Conclusions:
- Direct factor Xa and factor IIa inhibitors represent a promising advancement in anticoagulation.
- These new agents may replace conventional anticoagulants for long-term prevention and treatment of thromboembolic complications.
- Improved safety and predictability are key advantages of novel anticoagulants.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...